PRMT5 Inhibitor BMS-986504
Preclinical
PRMT5 Inhibitor BMS-986504 is one of 4 therapeutic programs targeting Metastatic Biliary Tract Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
3 competitors in Metastatic Biliary Tract Carcinoma
#DrugCompanyPhaseTrials
1Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Irinotecan Hydrochloride Liposome
Luye Pharma Group Ltd.Phase 2
Alimta
EEagle Pharmaceuticals, Inc.
Preclinical
PRMT5 Inhibitor BMS-986504
NNorthwestern University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for PRMT5 Inhibitor BMS-986504. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- NNorthwestern University